Trial Profile
Retrospective study of patients with metastatic renal cell carcinoma treated with nivolumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 29 Jul 2019 Results assessing predictive impact of peripheral blood markers and C-Reactive protein in nivolumab therapy in metastatci renal cell carcinoma patients, published in the Targeted Oncology.
- 28 Sep 2018 New trial record
- 19 Sep 2018 Results (n=40) published in the Targeted Oncology